Section Arrow
SKYE.NASDAQ
- Skye Bioscience
Quotes are at least 15-min delayed:2025/09/01 10:10 EDT
Regular Hours
Last
 3.5
+0.02 (+0.57%)
Day High 
3.605 
Prev. Close
3.48 
1-M High
4.0689 
Volume 
159.42K 
Bid
3.4
Ask
3.6
Day Low
3.3899 
Open
3.46 
1-M Low
2.96 
Market Cap 
107.84M 
Currency USD 
P/E 3.58 
%Yield -- 
10-SMA 3.46 
20-SMA 3.48 
50-SMA 3.67 
52-W High 7.11 
52-W Low 1.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.06/-1.93
Enterprise Value
108.11M
Balance Sheet
Book Value Per Share
1.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/09/01 10:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.